Clinical history of efavirenz

International Journal of Clinical Practice, Supplement

Volumn , Issue 103, 1999, Pages 3-7

  Ruiz, Nancy ^a  

^a DUPONT COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CYTOCHROME P450; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; OXAZINE DERIVATIVE;

ANTIVIRAL ACTIVITY; CONFERENCE PAPER; DRUG POTENCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; DRUG INTERACTION; REVIEW;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; CLINICAL TRIALS; DRUG INTERACTIONS; HUMANS; OXAZINES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0032585907     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (5)

1. Tashima K, Cu-Uvin S, Callendo A et al. Suppression of viral load in the genital tract and cerebrospinal fluid (CSF) in patients on combination therapy including efavirenz. (Poster 0554) 9th European Conference of Clinical Microbiology and Infectious Diseases, Berlin, March 1999.
2. Havlir D, Hicks C, Kahn J et al. Durability of antiviral activity of efavirenz (EFV, DMP 266) in combination with indinavir (IDV) [DMP 266-003, Cohort IV]. (Poster I-104) 38th ICAAC, San Diego, September 1998.
3. Jemsek J, Kagan S, Martin G et al. A Phase II open-label, multicenter study to characterize the effectiveness, safety, and pharmacokinetics of nelfinavir in combination with DMP 266 in antiretroviral therapy naïve or nucleoside analogue experienced HIV-infected patients [DMP 266-024]. (Poster I-102) 38th ICAAC, San Diego, September 1998.
4. AIDS clinical trials group (ACTG). Comparison of the virologic efficacy of nelfinavir (NFV) and/or efavirenz (EFV) with one of two new nucleoside analogues in nucleoside experienced subjects. (Poster) 12th World AIDS conference, Geneva, June 1998.
5. Haas DW, Fessel WJ, Delaphena RA et al. A Phase III, double blind, placebo-controlled, multicenter study to determine the effect and tolerability of the combination of efavirenz (EFV, SUSTIVA™, DMP 266) and indinavir (IDV) versus indinavir in HIV-1 infected patients receiving nucleoside analogue (NRTI) therapy at 36 weeks [DMP 266-020]. (Poster I-244) 38th ICAAC, San Diego, September 1998.